Integrin receptor antagonists
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 19, 2002
Grant Date -
N/A
app pub date -
Feb 22, 2000
filing date -
Nov 27, 1996
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
This invention relates to novel fused heterocycles which are useful as antagonists of the .alpha..sub.v.beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully